5 juni 2026 Sweden
Diamyd Medical reports that it has received several external proposals, including Letters of Intent and invitations to invest in various projects, as part of its ongoing strategic review. Following the discontinuation of the Phase III DIAGNODE-3 trial, the company is implementing cost-saving measures and evaluating strategic alternatives under the leadership of founder and CEO Anders Essen-Möller. Read the article here
|
26 maj 2026 Sweden
Umeå Biotech Incubator highlights Diamyd Medical’s GMP approval for its Umeå facility, noting its strategic importance for life science, regional preparedness and future pharmaceutical manufacturing. In the interview, Sofia Mayans, Head of Manufacturing Site Umeå, describes the approval as a major strength for the region. Read the full article here
|
21 maj 2026 Sweden
In an interview with BioStock, Sofia Mayans, Head of Manufacturing, comments on the GMP certification from the Swedish Medical Products Agency. The certification marks an important milestone for Diamyd Medical’s recombinant protein platform and strengthens the company’s position for future manufacturing, partnerships, and expansion opportunities. Read the article here
|
18 maj 2026 Sweden
I en intervju med Life Science Sweden berättar Sofia Mayans, Head of Manufacturing Site på Diamyd Medical, om bolaget utvärderar strategiska alternativ för sin anläggning i Umeå efter att fas III-studien med retogatein för typ 1-diabetes avslutats. Läs artikeln här
|
11 maj 2026 Sweden
In an interview with BioStock, Sofia Mayans, Head of Manufacturing Site at Diamyd Medical, commented on the positive feedback received from the Swedish Medical Products Agency after an inspection of the company’s Umeå facility. The inspection brings Diamyd Medical closer to GMP certification and a manufacturing license for its recombinant protein platform. The company also sees potential future opportunities in partnerships, CDMO services, and licensing. Read the article here
|